Association of polymorphisms in survivin gene with the risk of hepatocellular carcinoma in Chinese han population: a case control study

Yuhua Li1,2, Jiaofeng Wang1, Feng Jiang1, Wenyao Lin3 and Wei Meng1*

Abstract

Background: Survivin, one of the strongest apoptosis inhibitors, plays a critical role in the development and progression of hepatocellular carcinoma (HCC). By comparison, relatively little is known about the effect of survivin gene polymorphisms on HCC susceptibility. Our study aimed to investigate the association of survivin gene polymorphisms with the risk of HCC in Chinese han population.

Methods: A case-control study was conducted in Chinese han population consisting of 178 HCC cases and 196 cancer-free controls. Information on demographic data and related risk factors was collected for all subjects. Polymorphisms of the survivin gene, including three loci of rs8073069, rs9904341 and rs1042489, were selected and genotyped by a polymerase chain reaction- restriction fragment length polymorphism (PCR-RFLP) technique. Association analysis of genotypes/alleles and haplotypes from these loci with the risk of HCC was conducted under different genetic models.

Results: Using univariate analysis of rs8073069, rs9904341 and rs1042489 under different genetic models, no statistically significant difference was found in genotype or allele distribution of HCC cases relative to the controls (P > 0.05). Linkage disequilibrium (LD) analysis showed that these loci were in LD. Multivariate logistic regression indicated that with no G-C-T haplotype as reference, the haplotype of G-C-T from these loci was associated with a lower risk for HCC under the recessive model (OR = 0.46, 95% confidence interval (CI): 0.24–0.90, P = 0.023). Both HBsAg+ and the medical history of viral hepatitis type B were risk factors for HCC. However, no statistically significant haplotype-environment interaction existed.

Conclusions: No association between rs8073069, rs9904341 or rs1042489 in survivin gene and the risk of HCC is found in Chinese han population, but rs8073069G-rs9904341C-rs1042489T is perhaps a protective haplotype for HCC.

Background

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third most common cause of cancer-related death, which represents a major and constantly rising health burden throughout the world. In addition, HCC shows great geographical variation, with a very high incidence in China, where approximately 55% of annual new cases worldwide emerge [1,2]. Nowadays, the exact mechanism of hepatocarcinogenesis is still incompletely understood. However, a number of relevant molecules alter in some biological signals in the preneoplastic hepatocytes, especially the overactivation of anti-apoptotic signals, which disrupts the balance between survival and apoptotic signals [3]. It’s widely accepted that apoptosis plays a key role in cell or tissue homeostasis [4,5], dysregulation of apoptosis may induce the accumulation of virtually immortal cells and can ultimately lead to many human disorders, including cancer [6].

Survivin is a novel member of the inhibitor of apoptosis family of proteins (IAPs), containing a single baculovirus IAP repeat (BIR) domain [7]. It is involved in cell cycle regulation, inhibition of the apoptosis pathways and...
microtubule stability [8], playing a critical role in the
initiation and progression of tumorigenesis. Survivin
blocks both death receptor and mitochondrial apoptosis
pathways, by directly inhibiting caspase-3 and caspase-7
as well as by interfering with caspase-9 activity/process-
ing [9]. Furthermore, survivin inhibits apoptosis initiated
by various apoptotic stimuli such as IL-3, Fas, Bax, TNF-
α, anticancer drugs, and X-irradiation [10,11]. In addi-
tion, it’s reported that survivin was associated with angio-
genesis [12], which is critical in carcinogenesis. Survivin
is ubiquitous in embryonic or fetal tissues while unde-
tectable in most terminally differentiated normal adult
tissues [7]. By contrast, it is overexpressed in most
human cancers including HCC [13-17]. Moreover,
increased survivin expression in human malignancies is
considered to be an important marker for aggressive and
chemoresistant disease, thus signaling poor prognosis
[8,18-21].

Survivin is expressed in a cell cycle-regulated manner,
with a peak in the G2/M phase of the cell cycle, while it
rapidly declines in the G1 phase [22]. This is largely tran-
scriptionally controlled and involves cell cycle-dependent
elements (CDEs) and cell cycle homology regions (CHRs)
located in survivin gene promoter [23]. Several single
nucleotide polymorphisms (SNPs) have been identified in
survivin gene, such as -31G/C, -625G/C and -644C/T.
-31G/C polymorphism is a common mutation in cancer
cell lines leading to overexpression of survivin and the
aberrant cell cycle-dependent transcription, mediated via
functional disruption of binding at the CDE/CHR repres-
or motifs [24]. Several population-based studies indi-
cated survivin gene polymorphisms were associated with
human cancers [25-27]. However, to date, there was only
one report on the relationship between survivin gene
polymorphisms and the risk of HCC [28]. No similar
study has been conducted yet in Chinese population.

Based on the key role of survivin in carcinogenesis and
the association of survivin gene polymorphisms with its
expression and other cancers, we hypothesized that poly-
morphisms in survivin gene might modulate susceptibil-
ity to HCC. To test this hypothesis, we investigated the
association between survivin gene polymorphisms and the
risk of HCC in Chinese Han population.

Methods
Study Population and Samples Collection
This case-control study consisted of 178 HCC patients
and 196 cancer-free controls. All subjects were unrelated
Han nationality living in Haimen city, Jiangsu province.
HCC patients were diagnosed by doctors according to
the standards established by Chinese Society of Liver
Cancer (CSLC) [29]. Controls were matched with the
patients in terms of age and sex, excluding those with
medical history of surgery or chronic disease. Each
subject was personally face-to-face interviewed by trained
interviewers for information on demographic data as well
as related risk factors such as tobacco smoking, alcohol
drinking, medical history of viral hepatitis type B, et al. In
addition, approximately 5 ml venous blood was drawn
from each subject and preserved at -80°C. This research
protocol was approved by the Ethics Committee of
Fudan University, with the number IRB# 08-08-0142.

DNA Extraction and Genotyping
The genomic DNA was extracted from each blood sam-
ple using RelaxGenne Blood DNA system (TIANGEN,
Beijing). Each polymorphism of rs8073069, rs9904341
and rs1042489 was identified via the polymerase chain
reaction-restriction fragment length polymorphism
(PCR-RFLP) technique. The primers for PCR, the restric-
tion enzymes, and the fragments length after digestion
are shown in Table 1. Amplification was carried out on a
GeneAmp PCR System PTC-200 (MJ, American), PCR
mixture contained 50 ng of DNA, 9.5 μl ddH2O, 12.5 μl
2 × Taq PCR Master Mix (Laifeng, Shanghai), 1 μl
10 μmol/l each primer. The annealing temperature was
60.2°C, 64.4°C and 64.4°C for rs8073069, rs9904341 and
rs1042489 respectively. PCR products were digested by
the corresponding restriction enzymes (ChinaGen,
Shenzhen) and then separated by 2.0~3.0% agarose
gel electrophoresis with ethidium bromide (EB). The
genotypes are shown in Figure 1, 2 and 3. For double-
checking and quality control, 5% of the samples were
randomly selected to perform the repeated assays, and
the results were 100% concordant.

Statistical Analysis
Genotypes were tested for Hardy-Weinberg equilibrium
by an online soft http://ihg.gsf.de/cgi-bin/hw/hwa1.pl. Dif-
fferences in the distribution of genotypes or alleles under
different genetic models (including dominant, recessive,
additive and multiple models) within groups were esti-
mated by univariate statistical analyses (chi-square test) on
SPSS 16.0. Pair-wise linkage disequilibrium (LD) between
SNPs was calculated by Haploview 4.1. In addition, haplo-
types analysis was carried out by multivariate logistic
regression analysis on Hapstat 3.0. The odds ratios (ORs)
and 95% confidence intervals (CIs) were presented for
association analysis. For all hypothesis tests, a two-tailed
significance level of P < 0.05 was considered statistically
significant.

Results
General Characteristics of the Subjects
A total of 374 subjects were recruited in our study, includ-
ing 178 HCC cases and 196 controls. Their general
characteristics are summarized in Table 2. There was no
significant difference in age or gender between cases and
controls ($P = 0.343$ and 0.703 respectively). Besides, all subjects were local ethnic han population in Haimen, which indicated that both groups were comparable in demographic characteristics. With regard to the risk factors, Table 2 shows that the distributions of drinking, HBsAg+ and the medical history of viral hepatitis type B were significantly different within groups. Additionally, compared with the control subjects, the cases had a higher rate of smoke-quitting, but no difference was found between the proportion of subjects who never smoked and current smokers.

**Survivin Gene Polymorphisms of the Subjects**

The genotype and allele frequencies of rs8073069, rs9904341, rs1042489 in both HCC cases and controls are presented in Table 3, 4 and 5. The genotype distributions of the three polymorphisms didn’t significantly deviate from that expected for a Hardy-Weinberg equilibrium (for cases, $\chi^2 = 2.239$, 2.820 and 2.675 respectively; for controls, $\chi^2 = 0.143$, 0.078 and 1.451 respectively; all $P$ values were higher than 0.05), illustrating that our subjects presented the source population well. We compared the genotype or allele frequencies of every polymorphism within groups under the dominant, recessive, additive and multiple genetic models respectively. As shown in Table 3, 4 and 5, no significant differences were detected in the distributions of genotypes or alleles between case and control groups.

**Linkage Disequilibrium (LD) and Haplotype Analysis**

LD analysis showed that rs8073069 and rs9904341 were in strong LD, with the $r^2 = 0.288$, $D' = 0.916$, $D'^{95\%CI} (0.830\sim0.960)$; rs8073069 and rs1042489 were also in strong LD, with the $r^2 = 0.425$, $D' = 0.945$, $D'^{95\%CI} (0.880\sim0.980)$; rs9904341 and rs1042489 were in weak LD, with the $r^2 = 0.026$, $D' = 0.189$, $D'^{95\%CI} (0.070\sim0.290)$. These results stated clearly the three identified survivin gene polymorphisms were in LD.

With the help of multivariate logistic regression, factors like drinking, HBsAg+, the medical history of viral hepatitis type B and different haplotypes constructed by rs8073069-rs9904341-rs1042489 were included into models. As shown in Table 6 the recessive genetic model was the optimal one, according to the lowest vale of Akaike’s Information Criteria (AIC). With no G-C-T haplotype as reference, it was found that the haplotype of G-C-T from these loci was associated with a lower risk for HCC under the recessive model ($OR = 0.46$, $95\%CI: 0.24\sim0.90$, $P = 0.023$), whereas none of other significant haplotypes were found in this model. It also indicated that HBsAg+ and the medical history of viral hepatitis type B were risk factors for HCC, with the $OR$ being 27.03 ($P < 0.001$) and 55.16 ($P < 0.001$) respectively. However, no statistically

---

**Table 1 PCR-RFLP-based assay of survivin SNPs**

| SNP        | Position | Sequence of primer | Enzyme  | Interpretation(bp) |
|------------|----------|--------------------|---------|--------------------|
| rs8073069  | -625     | 5’- GTYCATTTTGCTTCATGCGC-3’ | Bsu I   | CC:164 CG:164,145 GG:145 |
| rs9904341  | -31      | 5’- GAGCAGCGGATGCTGGTG-3’ | Msp I   | GG:212,16 CC:120,92,16 CG:212,120,92,16 |
| rs1042489  | 3’UTR    | 5’- GCTTACCAGGAGAATGAGG-3’ | Msp I   | TT:476 TC:476,297,179 CC:297,179 |

**Figure 1** The genotypes of rs8073069 by PCR-RFLP.
significant haplotype-environment interaction was detected under different genetic models, as shown in Table 7.

Discussion

Survivin gene, located in 17q25, containing three exons and four introns, can encode an apoptosis inhibitor consisting of 142 amino acids. Nowadays, several SNPs have been identified in this gene [24]. The present case-control study explored the association of survivin gene polymorphisms with the risk of HCC in Chinese Han population for the first time. Our results suggested that none of rs8073069, rs9904341 or rs1042489 polymorphisms in survivin gene correlated with the susceptibility to HCC. The polymorphism of rs1042489 is in the 3' untranslated region of survivin gene, studies about this polymorphism haven't been reported yet. Our result showed that rs1042489 C/T polymorphism didn't correlate with the risk of HCC, indicating this polymorphism probably had nothing to do with the stability of survivin mRNA or its translational efficiency [30]. However, additional studies are required to clarify it.

The locus of rs8073069 (-625 G/C) is located in the promoter region of survivin gene. There were two studies on the relationship between this polymorphism and cancers, whereas no similar studies have been conducted on HCC. Yang et al. [25] launched a case-control study in Chinese population identifying that rs8073069-C
**Table 2** General characteristics of the cases and controls

| Factors          | Case            | Control         | \(P\)  | OR (95% CI) |
|------------------|-----------------|-----------------|--------|------------|
| Age (mean ± SD)  | 53.31 ± 8.41    | 52.48 ± 8.47    | 0.343  | -          |
| Sex n(%) Male    | 136(76.4)       | 153(78.1)       | -      | -          |
| Female           | 42(23.6)        | 43(21.9)        | 0.703  | -          |
| Smoking n(%)     |                 |                 |        |            |
| Never            | 71(39.9)        | 124(63.3)       | -      | 1          |
| Current          | 47(26.4)        | 67(34.2)        | 0.400  | 1.23 (0.76–1.97) |
| Quitting         | 60(33.7)        | 5(2.6)          | < 0.001| -          |
| Drinking n(%)    |                 |                 |        |            |
| No               | 101(56.7)       | 135(68.9)       | -      | 1          |
| Yes              | 77(43.3)        | 61(31.1)        | 0.015  | 1.69 (1.11–2.58) |
| HBsAg+ n(%)     |                 |                 |        |            |
| No               | 48(27.0)        | 184(93.9)       | -      | 1          |
| Yes              | 130(73.0)       | 12(6.1)         | < 0.001| 41.53 (21.22–81.26) |
| H+ n(%)          |                 |                 |        |            |
| No               | 105(59.0)       | 195(99.5)       | -      | 1          |
| Yes              | 73(41.0)        | 1(0.5)          | < 0.001| 135.57 (18.58–989.35) |

* The medical history of viral hepatitis type B

**Table 3** Frequency of rs8073069 genotypes/alleles under different genetic models

| Genetic Model | Genotypes/Alleles | Case n(%) | Control n(%) | \(\chi^2(P)\) | OR (95% CI) |
|---------------|-------------------|-----------|--------------|---------------|------------|
| Dominant      | CC                | 16(9.0)   | 12(6.1)      | -             | 1          |
|               | CG/GG             | 162(91.0) | 184(93.9)    | 1.11 (0.293)  | 0.66(0.30–1.44) |
| Recessive     | CC/GG             | 77(43.3)  | 89(45.4)     | -             | 1          |
|               | GG                | 101(56.7) | 107(54.6)    | 0.18 (0.676)  | 1.09(0.73–1.64) |
| Additive      | CC                | 16(9.0)   | 12(6.1)      | -             | 1          |
|               | CG                | 61(34.3)  | 77(39.3)     | -             | 0.59(0.26–1.35) |
|               | GG                | 101(56.7) | 107(54.6)    | 1.74 (0.420)  | 0.71(0.32–1.57) |
| Multiple      | C                 | 93(26.1)  | 101(25.8)    | -             | 1          |
|               | G                 | 263(73.9) | 291(74.2)    | 0.01 (0.911)  | 0.98(0.71–1.36) |

**Table 4** Frequency of rs9904341 genotypes/alleles under different genetic models

| Genetic Model | Genotypes/Alleles | Case n(%) | Control n(%) | \(\chi^2(P)\) | OR (95% CI) |
|---------------|-------------------|-----------|--------------|---------------|------------|
| Dominant      | CC                | 35(19.7)  | 52(26.5)     | -             | 1          |
|               | CG/GG             | 143(80.3) | 144(73.5)    | 2.47 (0.116)  | 1.48(0.91–2.40) |
| Recessive     | CC/GG             | 135(75.8) | 148(75.5)    | -             | 1          |
|               | GG                | 43(24.2)  | 48(24.5)     | 0.01 (0.940)  | 0.98(0.61–1.58) |
| Additive      | CC                | 35(19.7)  | 52(26.5)     | -             | 1          |
|               | CG                | 100(56.2) | 96(49.0)     | -             | 1.55(0.93–2.58) |
|               | GG                | 43(24.2)  | 48(24.5)     | 2.82 (0.244)  | 1.33(0.74–2.41) |
| Multiple      | C                 | 170(47.8) | 200(51.0)    | -             | 1          |
|               | G                 | 186(52.2) | 192(49.0)    | 0.80 (0.372)  | 1.14(0.86–1.52) |

**Table 5** Frequency of rs1042489 genotypes/alleles under different genetic models

| Genetic Model | Genotypes/Alleles | Case n(%) | Control n(%) | \(\chi^2(P)\) | OR (95% CI) |
|---------------|-------------------|-----------|--------------|---------------|------------|
| Dominant      | CC                | 31(17.4)  | 27(13.8)     | -             | 1          |
|               | CT/TT             | 147(82.6) | 169(86.2)    | 0.94 (0.331)  | 0.76(0.43–1.33) |
| Recessive     | CC/CT             | 130(73.0) | 129(65.8)    | -             | 1          |
|               | TT                | 48(27.0)  | 67(34.2)     | 2.28 (0.131)  | 0.71(0.46–1.11) |
| Additive      | CC                | 31(17.4)  | 27(13.8)     | -             | 1          |
|               | CT                | 99(55.6)  | 102(52.0)    | -             | 0.85(0.47–1.52) |
|               | TT                | 48(27.0)  | 67(34.2)     | 2.60 (0.273)  | 0.62(0.33–1.18) |
| Multiple      | C                 | 161(45.2) | 156(39.8)    | -             | 1          |
|               | T                 | 195(54.8) | 236(60.2)    | 2.25 (0.133)  | 0.80(0.60–1.07) |
allele was a risk factor for esophageal squamous cell carcinoma (ESCC), with the OR of CC genotype being 2.404 in contrast to GG genotype. Yang also described different survival expression levels between subgroups with different rs8073069 G/C variants in ESCC patients. His study suggested that rs8073069 G/C polymorphism was associated with the susceptibility to ESCC, perhaps by influencing survivin expression. However, Jang et al. [26] discovered that rs8073069 G/C polymorphism was not linked to the risk of lung cancer in Korea population. Our study indicated that rs8073069 G/C polymorphism didn’t correlate with the HCC in Chinese han population, this was consistent with Jang’s results, but inconsistent with Yang’s study. One suggestive explanation was that genetic susceptibility may be different to diverse cancers, other molecular and cellular mechanisms were probably involved in survivin overexpression in HCC. Besides, the negative results were perhaps due to the relatively small sample size, and therefore additional studies with larger samples are needed to validate our finding.

The locus of rs9904341 (-31 C/G) is located in survivin gene promoter. Several studies on the association of this polymorphism with cancers have been carried out. However their results were inconsistent. Jang et al. [26] discovered that individuals with at least one rs9904341-G allele had a significantly decreased risk for lung cancer compared to those with CC genotype. Promoter assay revealed G allele had a lower promoter activity than rs9904341-C allele. His results indicated this polymorphism regulated survivin expression, and thus modulated susceptibility to lung cancer. Maria et al. [31] found the association of this polymorphism with the risk of the sporadic colorectal cancer (CRC). Moreover, homozygotes for rs9904341-CC genotype expressed 1.6-fold higher mRNA levels of survivin compared to cases with other genotypes. Nonetheless, no correlation was found of rs9904341 C/G polymorphism with some cancers including ESCC, cervical cancer and acute myeloid leukemia [25,32,33]. In addition, Bayram et al. [28] demonstrated that there was no statistical association of rs9904341 C/G polymorphism with the risk of HCC in Turkish population. These inconsistent results may be attributable to differences in the pathways of carcinogenesis among various types of human cancers. The present study documented that rs9904341 was not associated with the risk of HCC in Chinese han population, it’s in line with Borbely’s study, suggesting that rs9904341 didn’t correlate with the risk of HCC. However, the negative result was perhaps due to the small sample size, so replication of this finding in larger samples is needed.

Haplotype analysis can obtain more information than single SNP and thus elevates the statistical power by making an assay of several SNPs within the same gene simultaneously [34]. LD analysis pointed out that these loci were in LD, therefore we made an assay of haplotypes

| Table 6 Analysis of haplotypes and environments under different genetic models |
|---------------------------------|-----------------|-----------------|-----------------|
| Factor                          | Dominant model  | Recessive model | Additive model  |
|                                 | β(P)            | OR(95%CI)       | β(P)            | OR(95%CI)       | β(P)            | OR(95%CI)       |
| Drinking                        | 0.00(0.999)     | 1.00(0.52~1.91) | 1.00(0.999)     | 1.00(0.52~1.91) | 1.00(0.999)     | 1.00(0.52~1.91) |
| HBsAg+                          | 3.30(0.001)     | 27.03(13.30~54.92) | 3.30(0.001)     | 27.03(13.30~54.92) | 3.30(0.001)     | 27.03(13.30~54.92) |
| H^b                             | 4.01(0.001)     | 55.16(17.10~428.57) | 4.01(0.001)     | 55.16(17.10~428.57) | 4.01(0.001)     | 55.16(17.10~428.57) |
| G-C-C^h                         | 0.12(0.624)     | 1.13(0.70~1.81) | 0.24(0.486)     | 1.27(0.65~2.45) | -0.12(0.843)     | 0.89(0.29~2.78) |
| G-C-C^h                         | 0.56(0.031)     | 1.75(0.75~2.92) | -0.07(0.894)    | 0.93(0.32~2.69) | 0.18(0.762)       | 1.20(0.37~3.90) |
| G-C-T^h                         | 0.07(0.775)     | 1.07(0.67~1.71) | -0.77(0.023)    | 0.46(0.24~0.90) | -0.32(0.574)     | 0.73(0.24~2.20) |
| G-G-T^h                         | 0.27(0.256)     | 1.31(0.82~2.11) | -0.17(0.652)    | 0.84(0.40~1.77) | -0.08(0.885)     | 0.92(0.30~2.86) |
| AIC                             | 1987.66         | 1986.23         | 1988.08         |

* The medical history of viral hepatitis type B; ^ The structure of G-C-T haplotypes was rs8073069-rs9904341-rs1042489; * The interaction between haplotype and environment.
constructed by the identified polymorphisms. With no G-C-T haplotype as reference, the haplotype of G-C-T was associated with a lower risk for HCC under the recessive genetic model (OR = 0.46, 95% CI: 0.24−0.90). This suggested G-C-T haplotype was perhaps a protective genetic factor for HCC in Chinese Han population. Nonetheless, it requires further studies to confirm. Both HBsAg+ and the medical history of viral hepatitis type B were risk factors for HCC, whereas no statistically significant haplotype-environment interaction existed.

To date, only one similar study on the correlation of survivin gene with HCC has been reported. Since polymorphisms often vary among different ethnic groups, additional and larger sample size studies are required to validate the association of survivin gene polymorphisms with HCC in diverse ethnic populations. However, our study was considered credible, suggesting survivin gene polymorphisms (rs8073069, rs9904341 or rs1042489) didn’t correlate with HCC, at least in Chinese Han population.

Conclusions
In conclusion, this is the first report regarding the association of the survivin gene polymorphisms with the risk of HCC in Chinese Han population. No association between rs8073069, rs9904341 or rs1042489 polymorphisms in survivin gene and the risk of HCC is found in the present study, but rs8073069G-rs9904341C-rs1042489T is perhaps a protective haplotype for HCC in Chinese Han population. Further studies will be needed to see whether survivin gene polymorphism has a role in HCC in other geographical region.

Author details
1Department of Epidemiology, School of Public Health, Fudan University; Key Laboratory of Public Health Security, Ministry of Education, Shanghai, 200032, China. 2Changing Center for Disease Control and Prevention, Shanghai, 200051, China. 3Haimen Center for Disease Control and Prevention, Jiangsu, 226100, China.

Authors’ contributions
The study’s chief researcher WM was responsible for identifying the research question, designing the study, obtaining ethics approval and overseeing the study. WL and FJ were in charge of the study fields, collecting subjects’ data. YL and JW majored in the laboratorial work, analyzing the data, writing the manuscript. All authors were responsible for drafting the manuscript, read and approved the final version.

Competing interests
The authors declare that they have no competing interests.

Received: 9 October 2010 Accepted: 3 January 2012 Published: 3 January 2012

References
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108.
2. Schütte K, Bornschein J, Walfherreiner P. Hepatocellular carcinoma—epidemiological trends and risk factors. Dig Dis 2009, 27(2):80-92.
3. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009, 15(5):513-520.
4. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267(5203):1456-1462.
5. Ruff M. Cell suicide for beginners. Nature 1998, 396(6707):119-122.
6. Haji RM, Liu JR. Apoptosome dysfunction in human cancer. Cancer Res 2004, 64(15):691-704.
7. Ambrosini G, Aldica C, Alten DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3(8):917-21.
8. Altreri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22(53):8581-8589.
9. Yamamoto T, Tanigawa N: The role of survivin as a new target of diagnosis and treatment in human malignancies. Med Electron Micros 2001, 34(4):207-212.
10. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998, 58(23):5315-5320.
11. Asamura K, Morsi R, Yajima T, Yajihashi A, Yamada M, Kobayashi D, Watanabe N: Survivin as a radiosensitizer factor in pancreatic cancer. Jpn J Cancer Res 2000, 91(11):1204-1209.
12. Kawasahi H, Toyoda M, Shimohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N: Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001, 91(11):2026-2032.
13. Ikeya M, Hirooka Y, Kaibara N: Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma. Cancer 2002, 95(9):1938-1945.
14. Gainsi R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehrer R, Shroyer KR. Expression of survivin in normal, hyperplastic, and neoplastic colon mucosa. Hum Pathol 2001, 32(1):119-125.
15. Kanta J, Konturek SJ, Malarz K, Hahn EG, Konturek PC. Expression of survivin and caspase-3 in gastric cancer. Dig Dis Sci 2003, 48(2):266-271.
16. Montoro M, Rosell R, Felipe E, Astudillo J, Sanchez JJ, Maestre J, Martin C, Font A, Barnadas A, Abad A: A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small cell lung cancers. J Clin Oncol 1999, 17(2):2100-2104.
17. Li F. Survivin study: what is the next wave. J Cell Physiol 2003, 197(1):8-29.
18. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawanoh H, Hayashida M, Nakano T, Suzuki A. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000, 31(5):1080-1085.
19. Kato J, Kuwabara Y, Mitanis M, Shioda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J, Fuji Y: Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001, 95(2):305-310.
20. Montorsi M, Maggioni M, Falleni M, Pellegrini C, Donadon M, Torzilli G, Santambrogio R, Spinelli A, Coggi G, Bosani S. Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology 2007, 54(92-93):3042-3044.
21. Li DX, Zeng B, Xie LQ: Expression and the clinical significance of survivin protein and β-catenin protein in primary hepatocellular carcinoma (HCC). Journal of Modern Oncology 2008, 16(1):62-66.
22. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Alten DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396(6711):580-584.
23. Altreri DC, Marchisio PC, Marchisio C. Survivin apoptoticin interloper between cell death and cell proliferation in cancer. Lab Invest 1999, 79(11):1327-1333.
24. Xu Y, Fang F, Ludewig G, Jones G, Jones D: A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 2004, 23(9):527-537.
25. Yang X, Xiong G, Chen X, Xu X, Wang K, Fu Y, Yang K, Bai Y: Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2009, 135(10):1341-1349.
26. Jang JS, Kim KM, Kang HK, Choi JE, Lee WK, Kim CH, Kang YM, Kim S, Kim JS, Jun JE, Jung TH, Park JY: Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 2008, 60(1):31-39.
27. Cheng ZH, Hu LH, Huang SJ: Correlation of -31G/C Polymorphisms of Survivin Promoter to Tumorigenesis of Gastric Carcinoma. Chinese Journal of Cancer 2008, 27(2):258-263.
28. Bayram S, Akkız H, Bekar A, Akgöllü E: The association between the survivin -31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiol 2011.

29. CSLC: The diagnostic standards of HCC.Chinese. Journal of Hepatology 2000, 8(3):135.

30. Chen S, He Y, Ding J, Jiang Y, Jia S, Xia W, Zhao J, Lu M, Gu Z, Gao Y: An insertion/deletion polymorphism in the 3’ untranslated region of beta-transducin repeat-containing protein (betaTrCP) is associated with susceptibility for hepatocellular carcinoma in Chinese. Biochem Biophys Res Commun 2010, 391(1):552-556.

31. Gazouli M, Tzanakis N, Rallis G, Theodoropoulos G, Papaconstantinou I, Kostakis A, Anagnostou NP, Nikiteas N: Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 2009, 24(2):145-150.

32. Borbély AA, Murvai M, Szarka K, Könya K, Gergely L, Hernádi Z, Veress G: Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 2007, 60(3):303-306.

33. Wagner M, Schmelz K, Dörken B, Tamm I: Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leukemia Research 2008, 32(7):1054-1060.

34. Morris RW, Kaplan NL: On the advantage of haplotype analysis in the presence of multiple disease susceptibility alleles. Genet Epidemiol 2002, 23(3):221-233.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/13/1/prepub

doi:10.1186/1471-2350-13-1
Cite this article as: Li et al.: Association of polymorphisms in survivin gene with the risk of hepatocellular carcinoma in Chinese han population: a case control study. BMC Medical Genetics 2012 13:1.